0001519692-22-000004.txt : 20220819 0001519692-22-000004.hdr.sgml : 20220819 20220819165215 ACCESSION NUMBER: 0001519692-22-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220818 FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greenstein Leonard M. CENTRAL INDEX KEY: 0001519692 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 221181407 MAIL ADDRESS: STREET 1: 24562 BELGREEN PLACE CITY: LAKE FOREST STATE: CA ZIP: 92630 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wf-form4_166094231301126.xml FORM 4 X0306 4 2022-08-18 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001519692 Greenstein Leonard M. C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 0 1 0 0 Chief Financial Officer Common Stock 2022-08-18 4 S 0 5000 16.30 D 64289 D The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.99 to $16.71. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. /s/ Leonard M. Greenstein 2022-08-19